BioVaxys Technology Corp News, BioVaxys Technology Corp Quote, BVAXF Quote

BioVaxys Technology Corp (OP:BVAXF) Delayed: 0.12 +0.02 (20.00%)

Prev. Close

$0.10

Today 6M 1Y 5Y

Open

$0.10

52 Wk High

$0.15

52 Wk Low

$0.08

Day High

$0.12

Day Low

$0.05

P/E

N/A

EPS

$0.00

Volume

17,126

Friends, Peers and Foes (?): BIOV, 5LB, HRZN FRA (more...)

ALERTS | RSS

Jan 20, 2026 08:04 AM BioVaxys reports positive phase 1B/2 ovarian cancer trial results
Jan 20, 2026 08:04 AM BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Ca
Jan 8, 2026 08:04 AM BioVaxys reports positive phase 1 results for bladder cancer vaccines
Jan 8, 2026 08:02 AM BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
Dec 17, 2025 08:03 AM BioVaxys reports positive phase 1 results for breast cancer treatment
Dec 17, 2025 08:03 AM BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Oct 14, 2025 08:01 AM BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

Entities mentioned with BVAXF

View All Entities